Archive: 28/04/2016

Costs for orally administered cancer drugs skyrocket

New cancer drugs, taken in pill form, have become dramatically more expensive in their first year on the market compared with drugs launched 15 years ago, calling into question the sustainability of a system that sets high ...

Cardiovascular giants Abbott, St. Jude in $25 bn merger

Abbott Laboratories and St. Jude Medical, leading makers of heart care and coronary devices, announced a $25 billion merger Thursday to better target the rising levels of cardiovascular disease in aging populations.

Harsh out of necessity

Multiple Sclerosis affects nearly 2 and a half million people worldwide. It is a highly debilitating autoimmune disease: the condition severely reduces patients' quality of life through symptoms which disrupt motor, cognitive, ...

page 7 from 11